U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H34N8O
Molecular Weight 474.6012
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEROCICLIB

SMILES

CC(C)N1CCN(CC1)C2=CN=C(NC3=NC4=C(C=C5N4C6(CCCCC6)CNC5=O)C=N3)C=C2

InChI

InChIKey=YPJRHEKCFKOVRT-UHFFFAOYSA-N
InChI=1S/C26H34N8O/c1-18(2)32-10-12-33(13-11-32)20-6-7-22(27-16-20)30-25-28-15-19-14-21-24(35)29-17-26(8-4-3-5-9-26)34(21)23(19)31-25/h6-7,14-16,18H,3-5,8-13,17H2,1-2H3,(H,29,35)(H,27,28,30,31)

HIDE SMILES / InChI
Molecular Formula C26H34N8O
Molecular Weight 474.6012
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
149124
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
27.2 ng/mL
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
33.8 ng/mL
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
43.9 ng/mL
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
325 ng × h/mL
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
395 ng × h/mL
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
710 ng × h/mL
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.1 h
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
200 mg 1 times / day multiple, oral
dose: 200 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
14.7 h
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
300 mg 1 times / day multiple, oral
dose: 300 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
15.5 h
OTHER
https://www.g1therapeutics.com/file.cfm/34/docs/le-G1_ESMO2019_Berz.pdf
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
LEROCICLIB plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Substance Class Chemical
Created
by admin
on Tue Apr 01 22:58:14 GMT 2025
Edited
by admin
on Tue Apr 01 22:58:14 GMT 2025
Record UNII
WBH8AY6ENB
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LEROCICLIB
INN   USAN  
Official Name English
2'-((5-(4-(PROPAN-2-YL)PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-7',8'-DIHYDROSPIRO(CYCLOHEXANE-1,9'(6'H)-PYRAZINO(1',2':1,5)PYRROLO(2,3-D)PYRIMIDIN)-6'-ONE
Preferred Name English
lerociclib [INN]
Common Name English
LEROCICLIB [USAN]
Common Name English
G1T38
Code English
SPIRO(CYCLOHEXANE-1,9'(6'H)-PYRAZINO(1',2':1,5)PYRROLO(2,3-D)PYRIMIDIN)-6'-ONE, 7',8'-DIHYDRO-2'-((5-(4-(1-METHYLETHYL)-1-PIPERAZINYL)-2-PYRIDINYL)AMINO)-
Systematic Name English
Lerociclib [WHO-DD]
Common Name English
G1T38 FREE BASE
Code English
7',8'-DIHYDRO-2'-((5-(4-(1-METHYLETHYL)-1-PIPERAZINYL)-2-PYRIDINYL)AMINO)SPIRO(CYCLOHEXANE-1,9'(6'H)-PYRAZINO(1',2':1,5)PYRROLO(2,3-D)PYRIMIDIN)-6'-ONE
Systematic Name English
G1T-38
Code English
Code System Code Type Description
SMS_ID
300000005945
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
NCI_THESAURUS
C138165
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
PUBCHEM
86269224
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
FDA UNII
WBH8AY6ENB
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
CAS
1628256-23-4
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
INN
11013
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
USAN
EF-75
Created by admin on Tue Apr 01 22:58:14 GMT 2025 , Edited by admin on Tue Apr 01 22:58:14 GMT 2025
PRIMARY
Related Record Type Details
CYCLIN-DEPENDENT KINASE 9
TARGET -> INHIBITOR
Structure of G1T38 DIHYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYCLIN-DEPENDENT KINASE 6
TARGET -> INHIBITOR
CYCLIN-DEPENDENT KINASE 4
TARGET -> INHIBITOR
Related Record Type Details
Structure of LEROCICLIB
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966